Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: A multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium

Researchers found that real-world data shows teclistamab is safe and effective for older RRMM patients (≥75). Safety outcomes (CRS/ICANS) and efficacy (ORR/PFS) were comparable to younger patients and pivotal trials. Advanced age alone should not preclude treatment; careful selection based on functional status is key.